首页> 外文OA文献 >Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO

【2h】

Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO

机译：液体活检允许在RAS / BRAF野生型MCRC患者（PTS）中具有耐素蛋白酶（CET）+ Irinotecan（IRI）的重新检查，具有耐受第一线CET + IRI：戈诺的最终结果和翻译分析的蟋蟀研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
D. Rossini; C. Cremolini; E. Conca; M. Del Re; A. Busico; F. Pietrantonio; F. Bergamo; R. Danesi; G. Cardellino; E. Tamburini; E. DellAquila; A. Strippoli; G. Masi; G. Tonini; F. Negri; D. Corsi; N. Pella; R. Intini; A. Falcone; D. Santini;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. 6113 BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients [J] . C.Cremolini, F.Loupakis, G.Perrone, European Journal of Cancer Supplements . 2009 ,第2期

机译：6113 BRAF V600E突变和两性调节蛋白（AR）免疫组化表达预测西妥昔单抗加伊立替康对KRAS野生型转移性结直肠癌（mCRC）患者的益处
2. 6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status [J] . E.Van Cutsem, P.Rougier, C.K?hne, European Journal of Cancer Supplements . 2009 ,第2期

机译：6077对西妥昔单抗联合化疗（CT）作为转移性结直肠癌（mCRC）患者（pts）的一线治疗的CRYSTAL和OPUS研究的荟萃分析：根据KRAS和BRAF突变状态得出的结果
3. 3055 POSTER Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study [J] . C.de Cerqueira Mathias, F.Perazzo, S.Simon, European Journal of Cancer Supplements . 2007 ,第4期

机译：3055 POSTER西妥昔单抗联合伊立替康在先前的伊立替康治疗期间或之后进展为转移性结直肠癌（mCRC）的患者（pts）：LABEL研究的最终结果
4. P-147Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment [O] . S. Yuki, Y. Komatsu, H. Nakatsumi, -1

机译：P-147最终分析：伊立替康/ S-1 /西妥昔单抗（IRIS / Cet）作为KRAS外显子2野生型mCRC患者的二线治疗的II期试验：HGCSG0902。西妥昔单抗治疗的给药间隔比较
5. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer [O] . Loupakis F, Ruzzo A, Cremolini C, 2009

机译：KRAS 61、146和BRAF密码子突变预测KRAS 12和13野生型转移性结直肠癌对西妥昔单抗加伊立替康的耐药性

Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO

著录项

相似文献

相关主题

期刊订阅